Many people only know AstraZeneca as one of the pharmaceutical giants that produced a COVID-19 vaccine in a short period. However, the company is working on other drugs, too. In fact, their breast cancer drug, Enhertu, showed excellent potential in recent trials. Here’s how Enhertu can help patients fight one of the most common cancers in the Philippines.
- Recent data on AstraZeneca’s Enhertu showed that it can help improve outcomes on HER2-low breast cancer patients by slowing tumor growth and improving survival.
- The findings are significant because HER2-low breast cancer patients are a part of the “unaddressed patient pool.” This is evidenced by the participants who have already exhausted 3 to 4 therapies.
- The drug, which is an antibody drug conjugate, combines a medicine that blocks HER2 protein and a chemotherapy medicine that inhibits replication of cancer cells.
- Enhertu is comparable to Kadcyla (by Roche), which combines Herceptin and another chemotherapy drug.